{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:57:16Z","timestamp":1768442236854,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.dsx.2021.102328","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T23:05:21Z","timestamp":1635548721000},"page":"102328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-6713","authenticated-orcid":false,"given":"Juan","family":"Gaztanaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravichandran","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann Marie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2366-8527","authenticated-orcid":false,"given":"Glenn","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshana","family":"Schendelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthinathan","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart D.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dsx.2021.102328_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"issue":"10229","key":"10.1016\/j.dsx.2021.102328_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.dsx.2021.102328_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.dsx.2021.102328_bib4","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"M.Circ Res."},{"key":"10.1016\/j.dsx.2021.102328_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046549","article-title":"Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia","volume":"7","author":"Son","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2021.102328_bib6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1161\/01.ATV.20.7.1745","article-title":"Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury","volume":"20","author":"Ruef","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.dsx.2021.102328_bib7","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/en.2017-00294","article-title":"Aldose reductase mediates NLRP3 inflammasome-initiated innate immune response in hyperglycemia-induced Thp1 monocytes and male mice","volume":"158","author":"Pal","year":"2017","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.dsx.2021.102328_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2337\/db13-0032","article-title":"Aldose reductase drives hyperacetylation of Egr-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals","volume":"63","author":"Vedantham","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2021.102328_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1096\/fj.03-1400com","article-title":"Central role for aldose reductase pathway in myocardial ischemic injury","volume":"11","author":"Hwang","year":"2004","journal-title":"Faseb J"},{"issue":"2","key":"10.1016\/j.dsx.2021.102328_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/diab.46.2.292","article-title":"Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury","volume":"46","author":"Ramasamy","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2021.102328_bib11","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.4049\/jimmunol.0900720","article-title":"Novel role for aldose reductase in mediating acute inflammatory responses in the lung","volume":"183","author":"Ravindranath","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.dsx.2021.102328_bib12","article-title":"Clinical assessment of AT-001, an aldose reductase inhihibitor in development for diabetic cardiomyopathy: a 28 day proof of concept study","volume":"16\u201319","author":"Perfetti","year":"2019","journal-title":"American Heart Association"},{"key":"10.1016\/j.dsx.2021.102328_bib13","series-title":"Preclinical and clinical Proof of Concept for Metabolic Intervention in diabetic cardiomyopathy","author":"Perfetti","year":"2019"},{"key":"10.1016\/j.dsx.2021.102328_bib14","series-title":"2 the ARISE-HF study \u2013 Development of AT-001 for the treatment of diabetic cardiomyopathy","author":"Nasrien Ibrahim","year":"2020"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121003489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402121003489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:15:35Z","timestamp":1761729335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402121003489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1871402121003489"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102328","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2021.102328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Diabetes India.","name":"copyright","label":"Copyright"}],"article-number":"102328"}}